Parkinson's disease
Drug research and approvals for parkinson's disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 513 studies of parkinson's disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 63 drug trials for it since 2013, FDA has 6 approved and 7 open orphan designations naming it, and the EU has 28 authorised medicines for it.
- Recruiting worldwide: 513
- Trials authorized in Canada: 63
- FDA orphan approvals: 6
- EU medicines: 28
- Impact of Remote Exercise on Sleep in PDNCT07949721 · Not applicable · University of Colorado, Denver · starts Oct 30, 2026
- Impact of Advanced Parkinson Therapies on Clinical Status: Deep Brain Stimulation and Foslevodopa/FoscarbidopaNCT07944859 · Not reported · Medical University of Warsaw · starts Mar 19, 2025
- Expiratory Muscle Strength Training for People With Parkinson's DiseaseNCT07932561 · Not applicable · Karolinska Institutet · starts Apr 8, 2024
- Virtual Reality for Motor and Cognitive Function in People With Parkinson's DiseaseNCT07931040 · Not applicable · Universidade Metodista de Piracicaba · starts Jun 1, 2026
- Exploratory Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's DiseaseNCT07911670 · Early Phase 1 · The First Affiliated Hospital of Anhui Medical University · starts Nov 23, 2026
- Strength and Dual-Task on Sarcopenia in People With Parkinson's DiseaseNCT07907302 · Not applicable · University of Valencia · starts Jan 11, 2027
- Parkinson's Disease in Type 1 Gaucher DiseaseNCT07886879 · Not reported · Icahn School of Medicine at Mount Sinai · starts Sep 21, 2026
- Ginger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's DiseaseNCT07882108 · Not applicable · Cambridge University Hospitals NHS Foundation Trust · starts Dec 17, 2025
- MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET)…NCT07880379 · Phase 1 · XingImaging, LLC · starts Aug 25, 2026
Approved 24 of 29
- LevodopaDopamine D3 receptor agonist
- CarbidopaDOPA decarboxylase inhibitor
- EntacaponeCatechol O-methyltransferase inhibitor
- RotigotineD2-like dopamine receptor agonist
- PramipexoleD2-like dopamine receptor agonist
- RasagilineMonoamine oxidase B inhibitor
- RopiniroleD2-like dopamine receptor agonist
- ApomorphineD2-like dopamine receptor agonist
- IstradefyllineAdenosine A2a receptor antagonist
- SafinamideMonoamine oxidase B inhibitor
- OpicaponeCatechol O-methyltransferase inhibitor
- PimavanserinSerotonin 2a (5-HT2a) receptor inverse agonist
- RivastigmineCholinesterases; ACHE & BCHE inhibitor
- AmantadineGlutamate [NMDA] receptor antagonist
- BromocriptineD2-like dopamine receptor agonist
- SelegilineMonoamine oxidase B inhibitor
- CabergolineDopamine D2 receptor agonist
- TolcaponeCatechol O-methyltransferase inhibitor
- IoflupaneDiagnostic agent
- Piribedil
- PergolideDopamine receptor agonist
- AtropineMuscarinic acetylcholine receptor M3 antagonist
- OrphenadrineHistamine H1 receptor antagonist
- TrihexyphenidylMuscarinic acetylcholine receptor M1 antagonist
Phase 3 12 of 35
- TavapadonDopamine D1 receptor partial agonist
- PerampanelGlutamate receptor ionotropic AMPA antagonist
- DopamineBeta-1 adrenergic receptor agonist
- DonepezilAcetylcholinesterase inhibitor
- PreladenantAdenosine A2a receptor antagonist
- PardoprunoxDopamine receptors; D2 & D3 partial agonist
- FoslevodopaBeta-1 adrenergic receptor agonist
- Ambroxol
- ExenatideGlucagon-like peptide 1 receptor agonist
- BenserazideDOPA decarboxylase inhibitor
- UbidecarenoneSupplement
- CaffeineAdenosine receptor antagonist
Phase 2 12 of 113
- FoligluraxMetabotropic glutamate receptor 4 positive allosteric modulator
- SipagladenantAdenosine A2a receptor inverse agonist
- Deferiprone
- MoxifloxacinTopoisomerase IV inhibitor
- NicotineNeuronal acetylcholine receptor; alpha4/beta2 agonist
- AcetylcysteineGlutathione precursor
- PrasinezumabAlpha-synuclein binding agent
- Glutathione
- Insulin humanInsulin receptor agonist
- VareniclineNeuronal acetylcholine receptor; alpha4/beta2 agonist
- MavoglurantMetabotropic glutamate receptor 5 antagonist
- VipadenantAdenosine A2a receptor antagonist
Phase 1 or earlier 12 of 52
- Resveratrol
- FlumazenilGABA-A receptor; anion channel allosteric antagonist
- Lithium carbonateInositol-1(or 4)-monophosphatase 1 inhibitor
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- RifampinBacterial DNA-directed RNA polymerase inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- PBF-509Adenosine A2a receptor antagonist
- CiforadenantAdenosine A2a receptor antagonist
- LiaterminGDNF family receptor alpha-1 agonist
- Indenebart
- AcetaminophenCyclooxygenase inhibitor
How its trials ended
3,950 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 648 whose ending is known, 42% met their primary endpoint, 6% missed it and 52% stopped early.
- Completed, result not reported1,77645%
- Ongoing92924%
- Status unknown59715%
- Met its primary endpoint2757%
- Stopped: other or unclear1905%
- Stopped: enrollment or feasibility722%
- Missed its primary endpoint391%
- Stopped: lack of efficacy261%
- Stopped: sponsor or business decision251%
- Stopped: funding18<1%
- Stopped: safety3<1%
| Sep 2, 2026 | A phase 2 study to evaluate the efficacy, pharmacokinetics, safety, and tolerability of VIM0423 in adults with Parkinson’s disease tremor insufficiently…VIM0423 (VMA-1001 / VMA-1002) | Vima Therapeutics, Inc. | Pending |
| Aug 20, 2026 | Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-model approachAtomoxetine | Radboud University Medical Center | Pending |
| Jul 31, 2026 | A phase 1 safety and feasibility trial of focused ultrasound enhanced delivry of recombinant glucocerebrosidase in participants with Parkinson's diseaseDefinity (perflutren) / Cerezyme | Sunnybrook Research Institute | Pending |
| Jan 2, 2026 | Early longitudinal imaging in the Parkinson’s progression markers initiative using [18f] AV-133 (ppmi AV-133 prodromal imaging)[18F] AV-133 | The Michael J Fox Foundation for Parkinson's Research | Pending |
| Sep 23, 2025 | A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants…Prasinezumab (RO7046015) | Roche | Ongoing |
| Sep 11, 2025 | First-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of intrathecally administered…Aln-snca | Regeneron | Ongoing |
| Sep 11, 2025 | A phase 2/3, double-blind, placebo controlled study of BHV-8000 in participants with early Parkinson's diseaseBHV-8000 | Biohaven Therapeutics | Pending |
| Sep 5, 2025 | Phase 3 study to assess the efficacy and safety of midbrain dopaminergic neuronal cell therapy (bemdaneprocel) for participants with Parkinson's diseaseBemdaneprocel / Basiliximab / Methylprednisolone acetate / Prednisone… | Bluerock Therapeutics Canada ULC | Ongoing |
| Aug 15, 2025 | A phase 1/2 dose-escalation trial to evaluate safety, tolerability, and efficacy of a single dose of CAP-003 gene therapy administered to patients with…CAP-003 / Dexamethasone / Prednisone | Capsida Biotherapeutics, Inc. | Pending |
| Dec 16, 2024 | Tallman family energizes research to help alleviate neuroinflammation in parkinsons disease-"taller than pd". a phase 2 futillity study to evaluate the…Hydroxychloroquine | Ottawa Hospital Research Institute | Ongoing |
| Feb 3, 2025 | OnapgoTreatment of motor fluctuations in adults with advanced Parkinson’s disease | MDD US Operations, LLC | Approved |
| Oct 16, 2024 | VyalevTreatment of motor fluctuations in adults with advanced Parkinson's disease (PD) | AbbVie, Inc. | Approved |
| Aug 24, 2017 | GocovriTreatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic… | Adamas Pharmaceuticals, Inc. | Approved |
| Jan 9, 2015 | DuopaTreatment of motor flucuations in patients with advanced Parkinson's disease | AbbVie, Inc. | Approved |
| Apr 20, 2004 | ApokynFor the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose-wearing-off" and unpredictable :on/off" episodes)… | MDD US Operations, LLC | Approved |
| Jun 5, 1989 | EldeprylAs an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism,… | Somerset Pharmaceuticals, Inc. | Approved |
| Feb 8, 2016 | Eltoprazine HClTreatment of levodopa-induced dyskinesia associated with Parkinson's disease. | Amarantus BioScience Holdings, Inc. | Designated |
| Oct 20, 1997 | ApomorphineFor use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease. | Scherer DDS | Designated |
| Jul 18, 1997 | Allogeneic human retinal pigment epithelial cells on…Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease. | Bayer Healthcare Pharmaceuticals, Inc. | Designated |
| Jun 24, 1997 | Porcine Sertoli cells aseptically prepared for…Treatment of Hoehn and Yahr stage four and five Parkinson's disease. | Titan Pharmaceuticals, Inc. | Designated |
| Dec 17, 1996 | Porcine fetal neural dopaminergic cells and/or precursors…Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease. | Diacrin/Genzyme LLC | Designated |
| Dec 17, 1996 | Porcine fetal neural dopaminergic cells and/or precursors…Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease. | Diacrin/Genzyme LLC | Designated |
| Jul 17, 1995 | ApomorphineTreatment of the on-off fluctuations associated with late-stage Parkinson's disease. | Pentech Pharmaceuticals, Inc. | Designated |
| Aug 20, 2026 | HopledoLevodopa; carbidopa | Zambon SpA | EMA ↗ |
| Apr 27, 2026 | OnerjiLevodopa; carbidopa | Tanabe Pharma GmbH | EMA ↗ |
| Sep 19, 2019 | InbrijaLevodopa | Merz Therapeutics GmbH | EMA ↗ |
| Jun 24, 2016 | OngentysOpicapone | Bial - Portela Cª, S.A. | EMA ↗ |
| Apr 4, 2016 | Rasagiline Viatris (previously Rasagiline Mylan)Rasagiline · generic | Viatris Limited | EMA ↗ |
| Feb 23, 2015 | XadagoSafinamide | Zambon SpA | EMA ↗ |
| Jan 12, 2015 | Rasagiline ratiopharmRasagiline | Teva B.V. | EMA ↗ |
| Nov 11, 2013 | Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)Levodopa; carbidopa; entacapone | Orion Corporation | EMA ↗ |
| Aug 23, 2011 | Levodopa/Carbidopa/Entacapone OrionLevodopa; carbidopa; entacapone | Orion Corporation | EMA ↗ |
| Aug 18, 2011 | Entacapone OrionEntacapone | Orion Corporation | EMA ↗ |
| Jun 16, 2011 | Rivastigmine ActavisRivastigmine · generic | Actavis Group PTC ehf | EMA ↗ |
| Feb 18, 2011 | Entacapone TevaEntacapone · generic | Teva Pharma B.V. | EMA ↗ |
| Dec 11, 2009 | Rivastigmine 1 A PharmaRivastigmine | 1 A Pharma GmbH | EMA ↗ |
| Dec 11, 2009 | Rivastigmine HexalRivastigmine | Hexal AG | EMA ↗ |
| Dec 10, 2009 | Rivastigmine SandozRivastigmine | Sandoz GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA